Anaptysbio (ANAB) Net Margin (2016 - 2026)
Anaptysbio's (ANAB) quarterly Net Margin came in at 206.93% in Q1 2026, down 6531.0% YoY from 3.22% in Q1 2025, and down 409.0% on a QoQ basis from 66.97% in Q4 2025.
Anaptysbio (ANAB) Net Margin (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 11 years of Net Margin data on file, last reported at 206.93% in Q1 2026.
- Quarterly Net Margin fell 6531.0% year-over-year to 206.93% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 15.15% (up 12471.0% YoY) and the FY2025 annual result came in at 5.38%, up 12022.0% from the prior year.
- Net Margin eased to 206.93% in Q1 2026, from 66.97% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 66.97% in Q4 2025 to a low of 5811.96% in Q1 2022.
- A 5-year average of 1312.91% and a median of 454.36% in 2022 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin sank 545825 bps — and 2024, when it jumped 394039 bps.
- Tracing ANAB's Net Margin over 5 years: stood at 454.36% in 2022, then declined by 3 bps to 468.27% in 2023, then soared by 107 bps to 34.87% in 2024, then jumped by 92 bps to 66.97% in 2025, then plunged by 409 bps to 206.93% in 2026.
- The last three Net Margin figures came in at 206.93% (Q1 2026), 66.97% (Q4 2025), and 30.23% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | -206.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -206.93% |
| Dec 31, 2025 | 66.97% |
| Sep 30, 2025 | 30.23% |
| Jun 30, 2025 | -173.52% |
| Mar 31, 2025 | -141.62% |
| Dec 31, 2024 | 34.87% |
| Sep 30, 2024 | -219.01% |
| Jun 30, 2024 | -425.30% |
| Mar 31, 2024 | -612.01% |
| Dec 31, 2023 | -468.27% |
| Sep 30, 2023 | -1,124.41% |
| Jun 30, 2023 | -1,151.59% |
| Mar 31, 2023 | -4,552.40% |
| Dec 31, 2022 | -454.36% |
| Sep 30, 2022 | -2,909.44% |
| Jun 30, 2022 | -4,200.74% |
| Mar 31, 2022 | -5,811.96% |
| Dec 31, 2021 | -3,177.74% |
| Sep 30, 2021 | -168.43% |
| Jun 30, 2021 | -131.02% |